LDCs open-ended waiver of WTO IPRs: drug prices, poverty & more
This article was originally published in Scrip
Mammoth price differentials between patented and locally produced drugs in a country where nearly 25 million people live in extreme poverty are some of justifications emerging from Bangladesh's promising pharmaceutical industry after the country led Least Developed Country (LDCs) members of the World Trade Organization (WTO) to seek an extension of the transitional period to enforce intellectual property rights on medicines.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.